Antiplatelet therapy in acute coronary syndromes

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 1, 2012, Pages 27-42

  Menozzi, Alberto ^a   Lina, Daniela ^a   Conte, Giulio ^a   Mantovani, Francesco ^a   Ardissino, Diego ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Acute coronary syndromes; Bleeding risk; Clopidogrel; Dual antiplatelet therapy; Ischaemic risk; Personalised medicine; Pharmacogenomics; Prasugrel; Ticagrelor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; CANGRELOR; CLOPIDOGREL; CYTOCHROME P450 2C19; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; KETOCONAZOLE; OMEPRAZOLE; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; RIFAMPICIN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VORAPAXAR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADD ON THERAPY; ANTICOAGULANT THERAPY; BLEEDING TENDENCY; BRADYCARDIA; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; GENETIC SCREENING; HEART INFARCTION; HUMAN; INHIBITION KINETICS; ISCHEMIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ASPIRIN; HUMANS; INTEGRIN BETA3; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTOR, PAR-1;

EID: 83455209954     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.642862     Document Type: Review

References (99)

1. Libby P. Current concepts of the pathogenesis of acute coronary syndromes. Circulation 2001;104:365-72
2. Davi G, Patrono C. Platelet activation and atherotrombosis. N Eng J Med 2007;357:2482-94
3. White HD. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. Am Heart J 2001;161:450-61
4. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55
5. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; Epub ahead of print
6. Kushner FG, Hand M, Smith SC Jr, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/ SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). Circulation 2009;120:2271-306
7. Wright RS, Anderson JL, Adams CD, et al. ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-STElevation Myocardial Infarction (Updating the 2007 Guidelines). Circulation 2011;123:2022-60.
8. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009;30:1457-66.
9. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
10. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
11. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 2003;108:1682-7
12. Mehta SR, Bassand JP, Chrolavicius S, et al. CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42
13. Desai NR, Bhatt DL. The state of periprocedural antiplatelet therapy after recent trials. J Am Coll Cardiol Intv 2010;3:571-83
14. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance.. J Am Coll Cardiol 2008;51:1829-43
15. Balsamo F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. Circulation 1990;82:17-26
16. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9
17. Bhatt DL, Bertrand ME, Berger BP, et al. Meta-analysis of randomized and registries comparison of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14
18. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
19. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.. Lancet 2001;358:527-33
20. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.. Lancet 2005;366:1607-21
21. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
22. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drug ticlopidine, clopidogrel, and prasugrel in humans.. J Clin Pharmacol 2010;50:126-42
23. Kurihara A, Hagihara K, Kazui M, et al. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev 2005;37(Suppl(2):89-99
24. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial.. J Am Coll Cardiol 2006;48:931-8
25. Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.. Br J Clin Pharmacol 2001;52:333-6
26. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.. Circulation 2003;107:2908-13
27. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.. J Am Coll Cardiol 2007;49:1505-16
28. Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis.. Thromb Haemost 2010;103:841-8
29. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.. Circulation 2004;109:3171-5
30. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.. Lancet 2010;376:1233-43
31. Hulot JS, Villard E, Azizi M, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.. Blood 2006;108:2244-7
32. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.. J Thromb Haemost 2007;5:2429-36
33. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.. Clin Pharmacokinet 2002;41:913-58
34. Holmes DR, Dehemer GJ, Kaul S, et al. ACCF/AHA Clopidogrel Clinical Alert: approaches to the FDA "Boxed Warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.. Circulation 2010;122:537-57
35. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel.. N Engl J Med 2009;360:354-62
36. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
37. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-18
38. Roden DM, Shuldiner AR. Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation 2010;122:445-8
39. Shuldiner AR, OConnell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
40. Mega JL, Close S, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-19
41. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2010;17:110-16
42. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011;32:1605-13
43. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
44. ODonoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
45. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
46. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051-66.
47. Bonello L, Tantry US, Marcucci R, et al. for the working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
48. Geisler T, Gawaz M, Steinhubl SR, et al. Current strategies in antiplatelet therapy. Does identification of risk and adjustment of therapy contribute to more effective, personalised medicine in cardiovascular disease? Pharmacol Ther 2010;127:95-107
49. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS randomized trial. JAMA 2011;305:1097-105
50. TRIGGER-PCI halted: Low events stymie platelet-reactivity trial with prasugrel, clopidogrel. Heartwire. Theheart.org. Available from: http:/www. theheart.org/article/1200057.do [Last accessed 1 July 2011]
51. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427-34
52. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8
53. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater and faster inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73
54. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30
55. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104
56. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:9-16
57. Wiviott SD, Trenk D, Ferelingeet AL. Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32.
58. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
59. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008;118:1626-36
60. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. Lancet 2009;373:723-31
61. Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22
62. Montalescot G, Bolognese L, Dudek D, et al. A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. Am Heart J 2011;161:650-6
63. Amsterdam EA, Peterson ED, Ou FS, et al. Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. Am Heart J 2009;158:748-54
64. Goodman SG, Huang W, Yan AT, et al. Expanded Global Registry of Acute Coronary Events (GRACE2) Investigators. The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. Am Heart J 2009;158:193-201
65. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
66. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/ OFFSET study. Circulation 2009;120:2577-85
67. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
68. Schneider DJMechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol 2011;57:685-7
69. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-93
70. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:3527
71. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84
72. Steg PG, James S, Robert A, Harrington RA, et al. for the PLATO Study Group. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation 2010;122:2131-41
73. Mahaffey KW, Wojdyla DM, Carrol K, et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011;[Epub ahead of print]
74. Ticagrelor approved at last for US market. Heartwire. Theheart.org. Available from: http://www.theheart.org/ article/1255445.do [Last accessed 26 July 2011]
75. Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) (NCT01225562). ClinicalTrials.gov. Available from: www. clinicaltrials.gov [Last accessed 24 October 2011].
76. Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010;50:27-35
77. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29
78. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41
79. A clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention (PCI) (CHAMPION PHOENIX) (NCT01156571). ClinicalTrials.gov. Available from: www. clinicaltrials.gov [Last accessed 1 July 2011].
80. Berge JS, Roe MT, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the early rapid reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trial. Am Heart J 2009;158:998-1004.
81. Leonardi S, Rao SV, Harrington RA, et al. Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-PCI). Am Heart J 2010;160:65-72
82. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005;3:1800-14
83. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-9
84. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51:3061-4
85. TRACER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: study design and rationale. Am Heart J 2009;158:327-34
86. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009;158:335-41
87. Van de Werf F. Inhibitors of the platelet thrombin receptor: Will They Live up to Their Promises? Circulation 2011;123:1833-5
88. Goto S, Ogawa H, Takeuchi M, et al. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010;31:2601-13
89. ODonoghue ML, Bhatt DL, Wiviott SD, et al. on behalf of the LANCELOT-ACS Investigators. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes. The lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 2011;123:1843-53
90. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98
91. De Luca G, Suryapranata H, Stone GW. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-65
92. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-8
93. Tricoci P, Newby LK, Hasselblad V, et al. Upstream use of small-molecule glycoprotein IIb/IIIa inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes 2011;4:448-58
94. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-90
95. Ellis SG, Tendera M, de Belder MA, et al. FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-17
96. ODonoghue ML, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 analysis. J Am Coll Cardiol 2009;54:678-85.
97. Hanna EB, Rao SV, Manoukian SV, Saucedo JF. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. J Am Coll Cardiol Cardiovasc Int 2010;3:1209-19
98. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-83
99. Verstuyft C, Simon T, Kim RB. Personalised medicine and antiplatelet therapy: ready for prime time? Eur Heart J 2009;30:1943-63